The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | When should patients with NHL be referred for CAR T-cell therapy?
LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, discusses the optimal time for patients with non-Hodgkin lymphoma (NHL) to receive chimeric antigen receptor (CAR) T-cell therapy. For patients with T-cell lymphoma, CAR-T cell therapy is recommended if they failed first-line therapy and earlier referrals can improve the quality of the product, as well as decrease waiting times for patients who need treatment. Cells can additionally be collected and frozen for later use, which reduces the need for cells that have been previously exposed to lymphodepleting agents. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
